# The MetNET-2 Trial

> **NCT02823691** · EARLY_PHASE1 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 20 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Lanreotide and Metformin

## Key facts

- **NCT ID:** NCT02823691
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823691, "The MetNET-2 Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02823691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*